9G2.SI drops 6.52% to S$0.043 intraday on 24 Feb 2026: watch liquidity risks
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2.SI stock) fell 6.52% intraday to S$0.043 on 24 Feb 2026 on the SES in Singapore. The move accelerated after an opening at S$0.046 and a session low of S$0.041 as volume reached 3,662,500 shares. Traders flagged weak liquidity and stretched balance-sheet ratios, while the stock trades below its 50-day average of S$0.060. This intraday decline keeps 9G2.SI stock among the top losers on the Singapore market and raises questions on near-term funding and margin recovery.
Intraday price action for 9G2.SI stock
9G2.SI stock opened at S$0.046 and slid to a low of S$0.041 during intraday trade on 24 Feb 2026. The one-day change was -6.52% and volume was 3,662,500, below the 30-day average of 4,788,842 shares. The stock is trading on the SES in SGD and remains volatile, with a 50-day average of S$0.060 and a 200-day average of S$0.04258.
Fundamentals and valuation: 9G2.SI stock analysis
Singapore Institute of Advanced Medicine Holdings Ltd. reports EPS -0.03 and a negative PE of -1.43, versus the Healthcare sector average PE of 22.98. Market cap stands at S$44,973,709.00 with 1,045,900,200 shares outstanding. Key ratios show a low current ratio of 0.27 and debt to equity of 1.77, indicating liquidity stress compared with the sector current-ratio average of 4.51. Price-to-book is 1.06, and price-to-sales is 2.82, signalling mixed valuation signals against weak profitability.
Technicals and trading signals for 9G2.SI stock
Technical indicators show oversold momentum for 9G2.SI stock. The RSI stands at 22.09, CCI at -210.00, and Williams %R at -86.67, consistent with short-term oversold conditions. Bollinger Bands sit at 0.04/0.05/0.06 (lower/mid/upper). Trading volume is light relative to the stock’s average, and on-balance volume remains elevated at 49,896,500, suggesting distribution during sell-offs.
Meyka AI grade and forecast for 9G2.SI stock
Meyka AI rates 9G2.SI with a score of 60.82 out of 100, Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects S$0.05 monthly, S$0.09 quarterly, and S$0.10610 yearly. Versus the current price S$0.043, the yearly projection implies +146.78% upside. Forecasts are model-based projections and not guarantees.
Risks and catalysts for 9G2.SI stock
Primary risks for 9G2.SI stock include weak liquidity, negative operating margins, and high debt ratios. Working capital is negative S$-16,944,687, and interest coverage is -5.69, raising refinancing concerns. Potential catalysts include improved lab services demand, cost-cutting that narrows operating losses, or capital raises that shore up the balance sheet. Watch news flow and any capital market activity closely.
Sector context and short-term trading strategy for 9G2.SI stock
Within Healthcare, the company sits in Medical – Care Facilities and underperforms sector metrics on margins and liquidity. The healthcare sector shows positive YTD performance of 9.32%, but 9G2.SI stock is down 41.10% YTD. Short-term traders should focus on volume confirmation and RSI recovery above 40 before considering long entries. Longer-term investors should seek clear balance-sheet improvement and revenue traction.
Final Thoughts
9G2.SI stock is a top intraday loser on 24 Feb 2026 after a -6.52% drop to S$0.043 on the SES. Fundamentals show negative earnings, tight liquidity and elevated debt ratios versus healthcare peers. Technicals are oversold, offering a possible short-term bounce if volume confirms. Meyka AI’s forecast model projects S$0.10610 over one year, implying +146.78% upside from S$0.043, but this relies on operational recovery and balance-sheet repairs. Forecasts are model-based projections and not guarantees. For now, analysts frame 9G2.SI stock as higher risk, suited to traders with strict risk controls or investors who expect capital restructuring and clearer cash flow improvement. Monitor filings, intraday volume, and any capital-raising announcements when reassessing positions.
FAQs
What drove the intraday drop in 9G2.SI stock on 24 Feb 2026?
The intraday drop was driven by weak liquidity and balance-sheet concerns. 9G2.SI stock fell 6.52% to S$0.043 amid below-average volume and negative margin metrics that raised short-term funding risk.
What is Meyka AI’s forecast for 9G2.SI stock?
Meyka AI’s forecast model projects S$0.05 monthly, S$0.09 quarterly and S$0.10610 yearly. These are model-based projections and not guarantees for 9G2.SI stock.
How does valuation of 9G2.SI stock compare with the healthcare sector?
9G2.SI stock posts a negative PE of -1.43 versus the healthcare sector average PE of 22.98. The company also has a low current ratio of 0.27, below the sector average of 4.51.
Should I trade 9G2.SI stock during this intraday weakness?
Intraday trading may suit experienced traders only. Look for volume confirmation, RSI recovery above 40, and clear news on capital or cash flow. 9G2.SI stock remains high risk.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.